Showing 5181-5190 of 6964 results for "".
- Psoriasis, Other Autoimmune Diseases Up Risk for CVDhttps://practicaldermatology.com/news/psoriasis-other-autoimmune-diseases-up-risk-for-cvd/2461323/Earlier research has suggested associations between some autoimmune disorders and a higher risk of cardiovascular disease, and now, a new study shows that nineteen of the most common autoimmune disorders seem to increase risk for developing heart disease. Patients with autoim
- Arcutis Rolls Out New Psoriasis Public Awareness Campaignhttps://practicaldermatology.com/news/arcutis-rolls-out-new-psoriasis-public-awareness-campaign/2461321/Arcutis Biotherapeutics, Inc. is launching an educational campaign designed to raise awareness about the physical and emotional impact of plaque psoriasis and empower those living with the disease to have open, honest conversations with their healthcare providers, family, and friends.
- Cutera Recognized by 50/50 Women on Boards for Gender-Balanced Board of Directorshttps://practicaldermatology.com/news/cutera-recognized-by-5050-women-on-boards-for-gender-balanced-board-of-directors/2461315/The 50/50 Women on Boards recognized Cutera for having a gender-balanced board. With four women directors, holding 50 percent of its corporate board seats, Cutera, Inc. is one of only 8 percent (just 241) of Russell 3000 companies with a gender-balanced board. &ldq
- La Roche-Posay Becomes the First-Ever Official Sunscreen of the US Openhttps://practicaldermatology.com/news/la-roche-posay-becomes-the-first-ever-official-sunscreen-of-the-us-open/2461314/La Roche-Posay is the official sunscreen partner of the US Open. Beginning with this year's US Open, La Roche-Posay will have a sun safety education booth in the South Plaza of the USTA Billie Jean King National Tennis Center, with two additional product sampling kiosks on the
- First Patient Dosed in Phase 1b/2 Trial of Dermaliq Therapeutics's DLQ02 for PsOhttps://practicaldermatology.com/news/first-patient-dosed-in-phase-1b2-trial-of-dermaliq-therapeuticss-dlq02-for-pso/2461310/The first patient has been dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor, Dermaliq Therapeutics, Inc. reports. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in patients with plaqu
- Amorepacific Introduces the World's First Chip-less Wireless Electronic Skin Enabled by Semiconductorshttps://practicaldermatology.com/news/amorepacific-introduces-the-worlds-first-chip-less-wireless-electronic-skin-enabled-by-semiconductors/2461309/Amorepacific has developed the world's first chip-less wireless wearable electronic skin (e-skin) that is sweatproof and can continuously monitor skin changes over long periods of time. The result follows four years of joint research between Professor Professor&
- Online Extra: Let’s Talk About Truncal Acnehttps://practicaldermatology.com/news/online-extra-lets-talk-about-truncal-acne/2461304/While often trivialized as a cosmetic skin disease, acne is in fact an inflammatory skin condition with a complex pathogenesis associated with a significant physical and psychological burden. Approximately 50% of people with facial acne also have truncal acne manifesting on the back, shoulders, a
- Rodan + Fields Gives Back: Company Announces More Donations from Youth Empowerment Fundhttps://practicaldermatology.com/news/rodan-fields-gives-back-company-announces-more-donations-from-youth-empowerment-fund/2461300/Rodan + Fields has announced the second round of donations from the Youth Empowerment Fund through their support of the Prescription for Change project. Launched in August 2021, the Fund will invest a total of $5 Million over three years to empower young people to l
- La Roche-Posay, American Cancer Society Partner to Improve Patient and Caregiver Quality of Lifehttps://practicaldermatology.com/news/la-roche-posay-american-cancer-partner-to-improve-patient-and-caregiver-quality-of-life/2461299/La Roche-Posay US is joining forces with the American Cancer Society (ACS) to further the support of cancer patients, survivors, caregivers, and the oncology community as well as raise awareness of cancer treatments' skin side effects. Since 1905, La Roche-Posay has been committed to improvin
- Epidural Nerve Block with Lidocaine Leads to Clearance of Psoriatic Skin Lesionshttps://practicaldermatology.com/news/epidural-nerve-block-with-lidocaine-leads-to-clearance-of-psoriatic-skin-lesions/2461297/Use of an epidural nerve block with lidocaine leads to clearance of psoriatic skin lesions, according to a novel proof-of-concept study in the Journal of Investigative Dermatology. “Case studies have shown that psoriasis patients have experienced significant symptom